Filing Flows › Adaptive Biotechnologies (ADPT) › Recalls, complaints & regulation
Adaptive Biotechnologies (ADPT): clinical trials
Adaptive Biotechnologies (ADPT) beyond its filings: 1 active clinical trial.
Adaptive Biotechnologies' latest quarter
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Adaptive Biotechnologies have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.